Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors

KHANMAMMADOV, NİJAT; Paksoy, Nail; VATANSEVER, SEZAI; Saip, Pınar; Aydiner, Adnan; Dogan, Izzet

doi:10.14744/ejp.2022.6003

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors

İzzet DOĞAN, (İstanbul Üniversitesi, Tıp Fakültesi, Onkoloji,Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Nijat KHANMAMMADOV, (İstanbul Üniversitesi, Tıp Fakültesi, Onkoloji,Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Nail PAKSOY, (İstanbul Üniversitesi, Tıp Fakültesi, Onkoloji,Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Sezai VATANSEVER, (İstanbul Üniversitesi, Tıp Fakültesi, Onkoloji,Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Pınar SAİP, (İstanbul Üniversitesi, Tıp Fakültesi, Onkoloji,Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Adnan AYDINER (İstanbul Üniversitesi, Tıp Fakültesi, Onkoloji,Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Eurasian Journal of Pulmonology

0 0

Yıl: 2023 Cilt: 25 Sayı: 1 Sayfa Aralığı: 27 - 32 Metin Dili: İngilizce DOI: 10.14744/ejp.2022.6003 İndeks Tarihi: 23-05-2023

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors

Öz:

BACKGROUND AND AIM: The aim of this study was to assess the factors affecting T790M mutation acquisition in epidermal growth factor receptor (EGFR)-mutant metastatic non-small cell lung cancer (mNSCLC) patients. METHODS: We evaluated the data of EGFR-mutant metastatic lung cancer patients who progressed under tyrosine kinase inhibitors (TKIs) retrospectively. Logistic regression analysis was used to examine the association between the acquisition of the T790M mutation and clinicopathological characteristics. RESULTS: The study enlisted the participation of 52 patients. Exon 19, Exon 21, and uncommon mutation distributions at diagnosis were 67.3%, 23.1%, and 9.6%, respectively. After the disease progressed under TKIs, the presence of T790M mutation was evaluated with liquid (75%) or tissue biopsies (25%). In 33 (63.5%) patients, T790M mutations were detected. Gender, age, de novo metastatic disease, primary tumor localization (left or right lung), number of metastatic sites, type of TKI, smoking, objective response, and type of biopsy were not statistically significant factors for T790M mutation acquisition in logistic regression analysis. However, progression-free survival (PFS) time (p=0.03) and EGFR inhibitor-related toxicity (p=0.004) were found as predictors of acquisition of T790M mutation. CONCLUSIONS: Due to the rarity of T790M mutations in EGFR-mutant mNSCLC patients treated with EGFR inhibitors, evidence of their acquisition is limited. In this study, we detected that the presence of EGFR inhibitor-related toxicity and PFS time longer than 12 months were predictors for T790M mutation acquisition.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154–62.
2. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892–911.
3. Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer 2015;113:1519–28.
4. Franek J, Cappelleri JC, Larkin-Kaiser KA, Wilner KD, Sandin R. Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer. Future Oncol 2019;15:2857–71.
5. Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, Bertolini F, et al. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. Crit Rev Oncol Hematol 2018;123:149–61.
6. Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med 2018;142:163–7.
7. Attili I, Karachaliou N, Conte P, Bonanno L, Rosell R. Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther 2018;18:1021–30.
8. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, et al. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer 2019;125:892–901.
9. Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Yoshimoto N, Suzumura T, et al. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2020;139:80–8.
10. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169–80.
11. Kwok WC, Ho JCM, Lam DCL, Lui MMS, Ip MSM, Tam TCC. When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival. Asia Pac J Clin Oncol 2021;17:e35–9.
12. Kawamura T, Kenmotsu H, Omori S, Nakashima K, Wakuda K, Ono A, et al. Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer. Clin Lung Cancer 2018;19:e247–52.
13. Chai CS, Liam CK, Poh ME, Ong DB, Pang YK, Cheah PL, et al. Predictors of acquired T790M mutation in patients failing first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer Manag Res 2020;12:5439–50.
14. Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, et al. The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Cancer Res Treat 2018;50:1294–303.
15. Ouyang W, Yu J, Huang Z, Chen G, Liu Y, Liao Z, et al. Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. J Cancer 2020;11:2060–7.
16. Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, et al. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer 2019;127:96–102.
17. Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH, Zhang XC, et al. A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. J Thorac Oncol 2017;12:1368–75.
18. Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Mechanisms of resistance to osimertinib. J Thorac Dis 2020;12:2851–8.
19. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16:5489–98.
20. Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, et al. Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan Oncology Group 8715L phase 2 randomized clinical trial. JAMA Oncol 2021;7:386–94.

APA	Dogan I, KHANMAMMADOV N, Paksoy N, VATANSEVER S, Saip P, Aydiner A (2023). Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. , 27 - 32. 10.14744/ejp.2022.6003
Chicago	Dogan Izzet,KHANMAMMADOV NİJAT,Paksoy Nail,VATANSEVER SEZAI,Saip Pınar,Aydiner Adnan Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. (2023): 27 - 32. 10.14744/ejp.2022.6003
MLA	Dogan Izzet,KHANMAMMADOV NİJAT,Paksoy Nail,VATANSEVER SEZAI,Saip Pınar,Aydiner Adnan Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. , 2023, ss.27 - 32. 10.14744/ejp.2022.6003
AMA	Dogan I,KHANMAMMADOV N,Paksoy N,VATANSEVER S,Saip P,Aydiner A Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. . 2023; 27 - 32. 10.14744/ejp.2022.6003
Vancouver	Dogan I,KHANMAMMADOV N,Paksoy N,VATANSEVER S,Saip P,Aydiner A Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. . 2023; 27 - 32. 10.14744/ejp.2022.6003
IEEE	Dogan I,KHANMAMMADOV N,Paksoy N,VATANSEVER S,Saip P,Aydiner A "Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors." , ss.27 - 32, 2023. 10.14744/ejp.2022.6003
ISNAD	Dogan, Izzet vd. "Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors". (2023), 27-32. https://doi.org/10.14744/ejp.2022.6003

APA	Dogan I, KHANMAMMADOV N, Paksoy N, VATANSEVER S, Saip P, Aydiner A (2023). Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. Eurasian Journal of Pulmonology, 25(1), 27 - 32. 10.14744/ejp.2022.6003
Chicago	Dogan Izzet,KHANMAMMADOV NİJAT,Paksoy Nail,VATANSEVER SEZAI,Saip Pınar,Aydiner Adnan Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. Eurasian Journal of Pulmonology 25, no.1 (2023): 27 - 32. 10.14744/ejp.2022.6003
MLA	Dogan Izzet,KHANMAMMADOV NİJAT,Paksoy Nail,VATANSEVER SEZAI,Saip Pınar,Aydiner Adnan Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. Eurasian Journal of Pulmonology, vol.25, no.1, 2023, ss.27 - 32. 10.14744/ejp.2022.6003
AMA	Dogan I,KHANMAMMADOV N,Paksoy N,VATANSEVER S,Saip P,Aydiner A Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. Eurasian Journal of Pulmonology. 2023; 25(1): 27 - 32. 10.14744/ejp.2022.6003
Vancouver	Dogan I,KHANMAMMADOV N,Paksoy N,VATANSEVER S,Saip P,Aydiner A Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors. Eurasian Journal of Pulmonology. 2023; 25(1): 27 - 32. 10.14744/ejp.2022.6003
IEEE	Dogan I,KHANMAMMADOV N,Paksoy N,VATANSEVER S,Saip P,Aydiner A "Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors." Eurasian Journal of Pulmonology, 25, ss.27 - 32, 2023. 10.14744/ejp.2022.6003
ISNAD	Dogan, Izzet vd. "Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors". Eurasian Journal of Pulmonology 25/1 (2023), 27-32. https://doi.org/10.14744/ejp.2022.6003